

Rating | Target | Estimate Change





Rating | Target | Estimate Change

5 January 2017



page 22 of 58






Source: Jefferies

Rating | Target | Estimate Change

5 January 2017




Source: Jefferies

Peter Welford, CFA, Equity Analyst, 44 (0) 20 7029 8668, pwelford@jefferies.com

Rating | Target | Estimate Change


5 January 2017



Source: Jefferies

Rating | Target | Estimate Change


5 January 2017



page 26 of 58


Rating | Target | Estimate Change

5 January 2017



Source: Jefferies


Rating | Target | Estimate Change



Source: Jefferies

Rating | Target | Estimate Change


5 January 2017



Source: Jefferies

Rating | Target | Estimate Change


5 January 2017



Source: Jefferies

Rating | Target | Estimate Change

5 January 2017




Source: Jefferies

Peter Welford, CFA, Equity Analyst, 44 (0) 20 7029 8668, pwelford@jefferies.com

Rating | Target | Estimate Change

5 January 2017




Source: Jefferies

Peter Welford, CFA, Equity Analyst, 44 (0) 20 7029 8668, pwelford@jefferies.com

Rating | Target | Estimate Change


5 January 2017



Source: Jefferies

Rating | Target | Estimate Change


5 January 2017



Source: Jefferies

Rating | Target | Estimate Change

5 January 2017




Source: Jefferies



Rating | Target | Estimate Change

5 January 2017



Source: Jefferies


Rating | Target | Estimate Change

OPRX-106 (TNF)

Phase II begins in

UC

5 January 2017



PRX-110 (AIR DNase) Interim Phase I/II data in CF from Pulmozyme

PRX-110 (AIR DNase) OPRX-106 (TNF) Phase I/II results in CF Phase II results in from Pulmozyme Phase III (BRIDGE) begins

PRX-102

in Fabry switching from Replagal

UC



Protalix


Mid-term catalysts

Near-term catalysts

4Q17

2018		2019		2020	
PRX-102	PRX-102	PRX-102	PRX-102	PRX-102	
Fabry Phase III	Fabry Phase III	Fabry Phase III	Potential US & EU	Potential US & EU	
(BALANCE) interim	(BRIDGE) data	(BALANCE) results	filings for Fabry	filings for Fabry	
vs. Fabrazyme	from Replagal	vs. Fabrazyme	disease	disease	

Convertible
\$15m bond due
(was \$69m; CP
\$5.76)




Jefferies

Source: Jefferies

Rating | Target | Estimate Change

5 January 2017




Jefferies

Source: Jefferies

Rating | Target | Estimate Change

5 January 2017




Source: Jefferies

page 39 of 58

Peter Welford, CFA, Equity Analyst, 44 (0) 20 7029 8668, pwelford@jefferies.com

Rating | Target | Estimate Change

5 January 2017



Source: Jefferies